Novavax, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John C.s Jacobs
- Full Time Employees
- 749
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 21 Firstfield Road Gaithersburg MD United States 20878
- IPO Date
- May 16, 1973
- CIK
- 0001000694
- Website
- novavax.com
- Similar Companies
- Business
- Novavax, Inc. (Nasdaq: NVAX; FSE: NVV1) is a biotechnology company that discovers, develops and commercializes vaccines to protect against serious infectious diseases using its proprietary recombinant protein nanoparticle technology platform combined with the Matrix-M adjuvant; the company offers Nuvaxovid (also known as Covovax and Novavax COVID-19 Vaccine, Adjuvanted), a protein subunit COVID-19 vaccine authorized for adults and adolescents as a primary series and booster; its pipeline includes COVID-influenza combination vaccine candidates, standalone influenza vaccines and next-generation COVID-19 vaccines; Matrix-M adjuvant is also licensed for use in third-party products such as the R21/Matrix-M malaria vaccine developed by the University of Oxford and Serum Institute of India. Founded in 1987 and headquartered in Gaithersburg, Maryland, USA, with key R&D and manufacturing for Matrix-M in Uppsala, Sweden, Novavax operates globally across the United States, Europe and other international markets, targeting governments, healthcare systems and individuals. Recent developments include a May 2024 co-exclusive licensing agreement with Sanofi for co-commercialization of Nuvaxovid from 2025, development of flu-COVID combination vaccines and non-exclusive access to Matrix-M adjuvant, providing Novavax with a $500 million upfront payment, up to $1.2 billion in milestones, tiered double-digit royalties, tiered mid-single-digit royalties on additional Sanofi Matrix-M products and a minority equity investment from Sanofi; in 2025, Novavax completed marketing authorization transfers of Nuvaxovid to Sanofi in the European Union and United States, triggering $50 million in milestone payments and securing $225 million in non-dilutive capital year-to-date; the company amended its Sanofi collaboration in September 2025 to broaden Matrix-M use in pandemic vaccine candidates, with Sanofi exploring further opportunities.
Company News
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened
Novavax shareholder Shah Capital to step back from activist role
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax Stock Falls Back: What's Going On?
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax Shorts on Edge as Russia Plague Fears Spread
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know